Drug Profile
Dendritic cell cancer vaccine - Cellonis Biotechnologies
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Cellonis Biotechnologies
- Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Glioma(Recurrent) in China (Parenteral)
- 30 Nov 2009 Phase-I clinical trials in Glioma in China (Parenteral)
- 31 Mar 2009 Preclinical trials in Glioma in China (Parenteral)